

PAPER

View Article Online
View Journal | View IssueCite this: *RSC Adv.*, 2018, 8, 37035

Synthesis of six-membered spirooxindoles via a chiral Brønsted acid-catalyzed asymmetric intramolecular Friedel–Crafts reaction†

Hui-Xuan Chen,^a Yaqi Zhang,^a Yuyang Zhang,^a Xuefeng He,^a Zhen-Wei Zhang,^{ab} Hao Liang,^a Wenhuan He,^a Xiaoding Jiang,^a Xiangmeng Chen^a and Liqin Qiu^{id}*^aReceived 9th August 2018
Accepted 17th October 2018

DOI: 10.1039/c8ra06710d

rsc.li/rsc-advances

By means of the direct condensation of *N*-aminoethylpyrroles and isatins, followed by a chiral phosphoric acid-catalyzed asymmetric intramolecular Friedel–Crafts reaction, a new class of valuable chiral 3',4'-dihydro-2'-*H*-spiro[indoline-3,1'-pyrrolo[1,2-*a*]pyrazin]-2-ones bearing a quaternary carbon stereocenter were successfully synthesized in good to excellent yields and with moderate to good enantioselectivities under mild reaction conditions.

Spirooxindoles, containing a spirocyclic system, are unique structural motifs found in a wide range of natural products and bioactive compounds.¹ For instance, Spirotryprostatin B (Fig. 1) was isolated from the fermentation broth of *Aspergillus fumigatus* and was shown to completely inhibit the G2/M progression of cell division in mammalian tsFT210 cells.² *Gelsemium* alkaloids (e.g. *gelsenicine*, *gelsedine* and *gelsedilam*) were isolated from the ancient medicine Yakatsu stored in the Shosoin Repository and exhibit a wide range of biological activities, including analgesic, anti-inflammatory, and antitumor effects.³ Besides, a considerable number of spirooxindoles display anticancer activity. For example, APG-115 and MI77301, which can effectively block the MDM2-p53 protein–protein interaction in cells as MDM2 inhibitors, are under clinical trials as promising anticancer drugs.⁴

Consequently, the unique structure of those compounds has attracted much attention from synthetic chemists.⁵ Some investigated strategies to access this skeleton include intramolecular reactions of imines via Pictet–Spengler reaction synthesized from tryptamines or tryptophans with isatin (Scheme 1a),⁶ oxidative rearrangement of tetrahydro-β-carbolines prepared via Pictet–Spengler reaction (Scheme 1b),⁷ metal or small-molecule catalyzed 1,3-dipolar cycloaddition of imino esters with methyleneindolinones (Scheme 1c),⁸ Rh-catalyzed [4 + 1] cycloaddition of azocompound with vinyl isocyanates (Scheme 1d),⁹ chiral iodoarene catalytic oxidative

spirocyclization (Scheme 1e),¹⁰ Pd-catalyzed intramolecular addition and domino spirocyclization,¹¹ intramolecular nucleophilic addition¹² and so on.¹³ Despite of several methods developed for the construction of this skeleton, however, less work finished catalytic asymmetric synthesis and preparation of novel chiral spirooxindoles are warmly anticipated. Herein, we report an efficient protocol via an intermolecular condensation/intramolecular Friedel–Crafts reaction to synthesize a new class of 3',4'-dihydro-2'-*H*-spiro[indoline-3,1'-pyrrolo[1,2-*a*]pyrazin]-2-ones in an asymmetric way.

At the outset of this study, we envisaged that reaction of *N*-aminoethylpyrroles with isatins catalyzed by chiral phosphoric acids might undergo direct condensation, followed by intramolecular Friedel–Crafts reactions under very mild reaction conditions.¹⁴ We first began our investigation with 1-benzylindole-2,3-dione (1.0 equiv.) and *N*-aminoethylpyrrole (1.2 equiv.) as the substrates, BINOL-derived chiral phosphoric acid **4a** as the catalyst, dichloromethane (DCM) as the solvent, 4 Å MS as a desiccant. The reaction was performed at room temperature (20 °C). To our delight, the cascade reaction proceeded smoothly providing 3',4'-dihydro-2'-*H*-spiro[indoline-3,1'-pyrrolo[1,2-*a*]pyrazin]-2-one **3aa** in 99% yield but with a poor enantioselectivity (5% ee, Table 1, entry 1). Encouraged by the excellent reactivity, we continued to screen several other chiral phosphoric acid catalysts derived

^aSchool of Chemistry, The Key Laboratory of Low-Carbon Chemistry & Energy Conservation of Guangdong Province, South China Sea Bio-Resource Exploitation and Utilization Collaborative Innovation Center, Sun Yat-Sen University, No. 135 Xingangxi Road, Guangzhou 510275, People's Republic of China. E-mail: qiu liqin@mail.sysu.edu.cn; Fax: +86-20-8411-0996

^bCollege of Pharmacy, Guangxi University of Chinese Medicine, Nanning 530200, People's Republic of China

† Electronic supplementary information (ESI) available: Copies of ¹H, ¹³C and ¹⁹F NMR spectra of products and HPLC spectra of products. See DOI: 10.1039/c8ra06710d





Fig. 1 Selected examples of natural and artificial spirooxindoles.



Scheme 1 Catalytic synthesis of spirooxindoles.

from BINOL under similar reaction conditions (Table 1). When chiral phosphoric acid **PA-4c** having a substituent 3,5-(CH₃)₂C₆H₃ at the 3,3'-positions was used, the reaction just only obtained moderate yield and low enantioselectivity (72% yield and 5% ee). Employment of bulkier catalyst (*R*)-**PA 4e** furnished the product in an excellent yield along with a moderate improvement in the enantioselection (99% yield and 21% ee). Catalysis by 2,4,6-triisopropylphenyl substituted phosphoric acid (*R*)-**PA 4i** generated good yield and moderate ee (96% yield and 49% ee). Inspired by List's work,¹⁵ we turned to employ another kind of spiro catalysts¹⁶ and investigated their function. Delightingly, catalyst (*R*)-**PA 5a** was found to significantly improve the ee from 49% to 88% and product **3aa** was given in 85% yield under mild reaction conditions in DCM. Then we evaluated the feasibility of the reaction in other solvents (Table 1, entries 12–17). It was observed that reaction in tetrahydrofuran had a high reactivity but only a moderate enantioselectivity. The ee values decreased significantly when polar solvents such as acetonitrile and *N,N*-dimethylformamide were used (Table 1, entries 13 and 14). Equivalent ee value was achieved using either ether or chloroform (81% and 90% yields; 79% and 78% ee's, respectively; Table 1, entries 15 and 16). Additionally, reaction in 1,4-dioxane acquired good yield and ee (Table 1, entry 17; 83% yield and 83% ee). 1,2-Dichloroethane (DCE) gave similar results as DCM too. Therefore, DCM was selected as the best solvent. Further studies on nitrogen-protecting groups revealed that all reactions proceeded smoothly for different substrates **1** of small or bulky group in this medium. However, negative influences on the enantioselection were

Table 1 Optimization of the reaction conditions^a

1a PG = Bn
1b PG = H
1c PG = Me
1d PG = *i*-Pr
1e PG = Ph₃C
1f PG = anthracen-9-ylmethyl
PA 4a: Ar = H
PA 4b: Ar = Ph
PA 4c: Ar = 3,5-(CH₃)₂C₆H₃
PA 4d: Ar = 3,5-(CF₃)₂C₆H₃
PA 4e: Ar = 3,5-(^tBu)₂C₆H₃
PA 4f: Ar = SiPh₃
PA 4g: Ar = 1-naphthyl
PA 4h: Ar = 9-anthryl
PA 4i: Ar = 2,4,6-(ⁱPr)₃C₆H₂
PA 5a: Ar = 2,4,6-(ⁱPr)₃C₆H₂
PA 5b: Ar = Ph


Entry	Substrate	(<i>R</i>)-PA	Solvent	Temp. [°C]	Yield ^b [%]	ee ^c [%]
1	1a	4a	DCM	r.t.	99	5
2	1a	4b	DCM	r.t.	99	0
3	1a	4c	DCM	r.t.	72	5
4	1a	4d	DCM	r.t.	99	0
5	1a	4e	DCM	r.t.	99	21
6	1a	4f	DCM	r.t.	99	0
7	1a	4g	DCM	r.t.	99	0
8	1a	4h	DCM	r.t.	97	0
9	1a	4i	DCM	r.t.	96	49
10	1a	5a	DCM	r.t.	85	88
11	1a	5b	DCM	r.t.	70	19
12	1a	5a	THF	r.t.	99	80
13	1a	5a	MeCN	r.t.	68	62
14	1a	5a	DMF	r.t.	28	44
15	1a	5a	Et ₂ O	r.t.	81	79
16	1a	5a	CHCl ₃	r.t.	90	78
17	1a	5a	1,4-Dioxane	r.t.	83	83
18	1a	5a	DCE	r.t.	84	87
19	1b	5a	DCM	r.t.	89	39
20	1c	5a	DCM	r.t.	68	68
21	1d	5a	DCM	r.t.	97	74
22	1e	5a	DCM	r.t.	84	74
23	1f	5a	DCM	r.t.	92	69
24	1a	5a	DCM	0	71	79
25	1a	5a	DCM	30	90	80

^a Reaction conditions: **1a** (0.2 mmol), **2a** (1.2 equiv.), (*R*)-**PA** (10 mol%), 4 Å MS (50 mg), 2.0 mL of solvent, r.t. = 20 °C, overnight. ^b Isolated yield.

^c ee was determined by chiral HPLC.

showed for the substrates without protecting group or with a small protecting group (39% and 68% ee's, respectively, Table 1, entries 19 and 20). In spite of bulky *N*-protecting group being beneficial to get high yield, the enantioselectivity decreased a little (97%, 84% and 92% yields; 74%, 74% and 69% ee's, respectively; Table 1, entries 21–23). So, benzyl-protected substrate is the best choice for the reaction. Temperature effect was also explored. Conducting the reaction at 0 or 30 °C instead of at room temperature, a noticeable drop in enantioselectivity was observed (79% and 80% ee's respectively, entries 24 and 25). Overall, the model reaction generated the desired product in highest yield in DCM at 20 °C with benzyl-protected **1a** as the substrate, **PA-5a** as the catalyst, 4 Å MS as the desiccant.




Table 2 Scope of isatin substrates^{a,b,c}

^a Reaction conditions: **1a** (0.2 mmol), **2a** (1.2 equiv.), *(R)*-PA **5a** (10 mol%), 4 Å MS (50 mg), 2.0 mL of solvent, overnight. ^b Isolated yield. ^c ee was determined by chiral HPLC.

With the set of optimized reaction conditions in hand, we focused our attention on the substrate scope of this catalytic asymmetric intramolecular Friedel-Crafts reaction. At first, substituted isatin derivatives were screened as the substrates in combination with *N*-aminoethyl pyrrole **2a**, affording chiral products **3**, 4'-dihydro-2'-*H*-spiro[indoline-3,1'-pyrrolo[1,2-*a*]pyrazin]-2-ones in moderate to excellent yields (Table 2). Halogen substitutions at C5 positions of the isatins were tolerated but lower ee values were given for **3ga**, **3ha** and **3ia** (79%, 90% and 92% yields; 61%, 37% and 32% ee's respectively). Reaction of isatins bearing an electron-donating group (5-methyl, **3ja** and 5-methoxy, **3ka**) or a strong electron-withdrawing group (5-nitro, **3la**) achieved relatively lower ee values, which was possibly attributed to two reasons: (1) hydrogen-bonding interactions between the isatin substituents and the catalyst; (2) steric hindrance between the isatin substituents and the catalyst. Obviously, strong hydrogen-bonding interaction led to decrease of the ee value for **3ma** (15% ee, 4-fluoro). On the contrary, the ee values for **3na** and **3oa** increased (61% and 61% ee's respectively) when the fluorine group was far from the reactive position. In addition, much bulkier 7-isopropyl substituent proved viable and the corresponding product **3pa** was obtained with a good ee value (79% ee).

Next, the substrate scope of *N*-aminoalkylpyrroles was also investigated. As shown in Table 3, 2-methyl substituted pyrrole

Table 3 Scope of pyrrole substrates^{a,b,c}

^a Reaction conditions: **1a** (0.2 mmol), **2a** (1.2 equiv.), *(R)*-PA **5a** (10 mol%), 4 Å MS (50 mg), 2.0 mL of solvent, overnight. ^b Isolated yield. ^c ee was determined by chiral HPLC.

maintained good reactivity and provided product **3ab** in 79% yield with a lower ee of 49%. Introduction of another methyl group at C3 position of the pyrrole ring resulted in lower reactivity and enantioselectivity in comparison to those of the monosubstituted product **3ab** (**3ac**, Table 3). In the presence of a Brønsted acid (*p*-toluenesulfonic acid), racemic **3ad'** was formed with good regioselectivity (**3ad/3ad'** = 5 : 1 determined by ¹H NMR), while chiral catalyst *(R)*-PA **5a** gave nearly equal amounts of **3ad** and **3ad'** (**3ad/3ad'** = 1 : 1.12). Moderate to good enantioselectivities were obtained (46% and 84% ee's respectively for **3ad** and **3ad'**, Table 3), albeit with poor regioselectivity. We presumed that the poor regioselectivity might come from the steric hindrance between chiral phosphoric acid **PA 5a** and the C3-ethyl group of the pyrrole. The cyclization of *N*-amino-propylpyrrole with isatin **1a** could also furnish the corresponding product **3ae**, but both the reactivity and enantioselectivity were poor (9% yield, 12% ee, Table 3). Employing *N*-aminoethylindole **2f** instead of *N*-amino-alkylpyrroles, the obtained result for product **3f** was still satisfactory (73% yield and 80% ee). Similar to di-substituted pyrrole, reaction of 3-methylindole also gained a low ee value (**3ac** and **3ag**, Table 3), which could also be attributed to the increased steric hindrance on chiral phosphoric acid **PA5a** introduced in proximity to the reactive position.







Fig. 2 Scale-up reaction.



Scheme 2 Proposed reaction pathway and activation mode.

Furthermore, a scale up reaction of **1a** and **2a** was performed, generating product **3aa** in 89% yield and 82% ee (Fig. 2).

Finally, based on the experimental results, together with related studies on CPA-catalyzed reactions,^{5f–5i} we proposed a possible reaction pathway to explain the stereochemistry of the formation of spirooxindoles **3** (Scheme 2). Isatins **1** initially participated in a Mannich reaction with *N*-aminoethylpyrroles **2**, affording transient intermediates **6** under the catalysis of Brønsted acid. Through the dual-hydrogen-bond, (*R*)-CPA **5a** interacted with intermediates **6** to realize their catalysis and stereocontrol. The enantioenriched spirooxindoles **3** were subsequently yielded *via* the intramolecular Friedel-Crafts reaction of intermediates **6**.

Conclusions

In conclusion, we have developed a direct catalytic asymmetric intramolecular Friedel-Crafts reaction of *N*-aminoethylpyrrole derivatives with isatin derivatives catalyzed by chiral phosphoric acids. This one-pot sequence provides a simple and efficient approach to preparing the new class of 3',4'-dihydro-2'*H*-spiro[indoline-3,1'-pyrrolo[1,2-*a*]pyrazin]-2-ones in good to excellent yields with moderate to good enantioselectivities under mild reaction conditions. Further work with respect to the extension and applications of this methodology is ongoing in our laboratory.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

We would like to thank Science and Technology Program of Guangzhou (201510010080), Special Financial Fund of Innovative Development of Marine Economic Demonstration Project (GD2012-D01-001), Nansha District Research Project (2016GG007), Guangzhou Lee & Man Technology Company

Limited, National Undergraduate Students Innovation and Entrepreneurship Training Program for financial support.

Notes and references

- For selected reviews, see: (a) C. V. Galliford and K. A. Scheidt, *Angew. Chem., Int. Ed.*, 2007, **46**, 8748–8758; (b) N. Ye, H. Chen, E. A. Wold, P.-Y. Shi and J. Zhou, *ACS Infect. Dis.*, 2016, **2**, 382–392; (c) B. Yu, D.-Q. Yu and H.-M. Liu, *Eur. J. Med. Chem.*, 2015, **97**, 673–698.
- (a) C.-B. Cui, H. Kakeya and H. Osada, *J. Antibiot.*, 1996, **49**, 832–835; (b) C.-B. Cui, H. Kakeya and H. Osada, *Tetrahedron*, 1996, **52**, 12651–12666.
- M. Kitajima, T. Nakamura, N. Kogure, M. Ogawa, Y. Mitsuno, K. Ono, S. Yano, N. Aimi and H. Takayama, *J. Nat. Prod.*, 2006, **69**, 715–718.
- (a) Y. Zhao, L. Liu, W. Sun, J. Lu, D. McEachern, X. Li, S. Yu, D. Bernard, P. Ochsenbein, V. Ferey, J. Carry, J. R. Deschamps, D. Sun and S. Wang, *J. Am. Chem. Soc.*, 2013, **135**, 7223–7234; (b) Y. Zhao, A. Aguilar, D. Bernard and S. Wang, *J. Med. Chem.*, 2015, **58**, 1038–1052; (c) A. Aguilar, J. Lu, L. Liu, D. Du, D. Bernard, D. McEachern, S. Przybranowski, X. Li, R. Luo, B. Wen, D. Sun, H. Wang, J. Wen, G. Wang, Y. Zhai, M. Guo, D. Yang and S. Wang, *J. Med. Chem.*, 2017, **60**, 2819–2839.
- (a) D. Cheng, Y. Ishihara, B. Tan and C. F. Barbas III, *ACS Catal.*, 2014, **4**, 743–762; (b) R. Narayan, M. Potowski, Z.-J. Jia, A. P. Antonchick and H. Waldmann, *Acc. Chem. Res.*, 2014, **47**, 1296–1310; (c) N. R. Ball-Jones, J. J. Badillo and A. K. Franz, *Org. Biomol. Chem.*, 2012, **10**, 5165–5181; (d) M. M. M. Santos, *Tetrahedron*, 2014, **70**, 9735–9757; (e) G. M. Ziarani, N. H. Nasaba and N. Lashgarib, *RSC Adv.*, 2016, **6**, 38827–38848; (f) G.-J. Mei and F. Shi, *Chem. Commun.*, 2018, **54**, 6607–6621; (g) A. Preetam and M. Nath, *RSC Adv.*, 2015, **5**, 21843–21853; (h) A. Alizadeh and J. Mokhtari, *Tetrahedron*, 2013, **69**, 6313–6316; (i) A. Kamal, R. Mahesh, V. L. Nayak, K. S. Babu, G. B. Kumar, A. B. Shaik, J. S. Kapure and A. Alarifi, *Eur. J. Med. Chem.*, 2016, **108**, 476–485; (j) X. Zhao, X. Liu, Q. Xiong, H. Mei, B. Ma, L. Lin and X. Feng, *Chem. Commun.*, 2015, **51**, 16076–16079; (k) J. Zheng, L. Lin, K. Fu, H. Zheng, X. Liu and X. Feng, *J. Org. Chem.*, 2015, **80**, 8836–8842; (l) C. Yin, L. Lin, D. Zhang, J. Feng, X. Liu and X. Feng, *J. Org. Chem.*, 2015, **80**, 9691–9699; (m) X. Lian, S. Guo, G. Wang, L. Lin, X. Liu and X. Feng, *J. Org. Chem.*, 2014, **79**, 7703–7710; (n) J. Guo, Y. Liu, X. Li, X. Liu, L. Lin and X. Feng, *Chem. Sci.*, 2016, **7**, 2717–2721; (o) X. Liu, H. Zheng, Y. Xia, L. Lin and X. Feng, *Acc. Chem. Res.*, 2017, **50**, 2621–2631; (p) T. Kang, P. Zhao, J. Yang, L. Lin, X. Feng and X. Liu, *Chem.-Eur. J.*, 2018, **24**, 3703–3706; (q) D. Zhang, L. Lin, J. Yang, X. Liu and X. Feng, *Angew. Chem., Int. Ed.*, 2018, **57**, 12323–12327.
- (a) S. Duce, F. Pesciaoli, L. Gramigna, L. Bernardi, A. Mazzanti, G. Bartoli and G. Bencivenni, *Adv. Synth. Catal.*, 2011, **353**, 860–864; (b) J. J. Badillo, A. Silva-García, B. H. Shupe, J. C. Fettingier and A. K. Franz, *Tetrahedron Lett.*, 2011, **52**, 5550–5553.



- 7 (a) F. von Nussbaum and S. J. Danishefsky, *Angew. Chem., Int. Ed.*, 2000, **39**, 2175–2178; (b) G. O. Fonseca, Z.-J. Wang, O. A. Namjoshi, J. R. Deschamps and J. M. Cook, *Tetrahedron Lett.*, 2015, **56**, 3052–3056; (c) S. Edmondson, S. J. Danishefsky, L. Sepp-Lorenzino and N. Rosen, *J. Am. Chem. Soc.*, 1999, **121**, 2147–2155; (d) X. Z. Wearing and J. M. Cook, *Org. Lett.*, 2002, **4**, 4237–4240.
- 8 (a) X. H. Chen, Q. Wei, S. W. Luo, H. Xiao and L. Z. Gong, *J. Am. Chem. Soc.*, 2009, **131**, 13819–13825; (b) A. Awata and T. Arai, *Chem.–Eur. J.*, 2012, **18**, 8278–8282; (c) T. Arai, H. Ogawa, A. Awata, M. Sato, M. Watabe and M. Yamanaka, *Angew. Chem., Int. Ed.*, 2015, **54**, 1595–1599; (d) N. Lashgari and G. M. Ziarani, *ARKIVOC*, 2012, 277–320; (e) X.-A. Xiao, H.-G. Zhang, S. Liang, J.-W. Ren, H. Yang and X.-Q. Chen, *J. Org. Chem.*, 2013, **78**, 11577–11583; (f) G. Zhu, Q. Wei, H. Chen, Y. Zhang, W. Shen, J. Qu and B. Wang, *Org. Lett.*, 2017, **19**, 1862–1865; (g) Y.-M. Wang, H.-H. Zhang, C. Li, T. Fan and F. Shi, *Chem. Commun.*, 2016, **52**, 1804–1807; (h) W. Dan, X.-J. Jiang, Q. Wu, F. Shi and S.-J. Tu, *J. Org. Chem.*, 2015, **80**, 5737–5744; (i) C.-S. Wang, R.-Y. Zhu, J. Zheng, F. Shi and S.-J. Tu, *J. Org. Chem.*, 2015, **80**, 512–520; (j) W. Dai, H. Lu, X. Li, F. Shi and S.-J. Tu, *Chem.–Eur. J.*, 2014, **20**, 11382–11389.
- 9 J. L. Meloche and B. L. Ashfeld, *Angew. Chem., Int. Ed.*, 2017, **56**, 6604–6608.
- 10 (a) J. Wang, Y. Yuan, R. Xiong, D. Zhang-Negrerie, Y. Du and K. Zhao, *Org. Lett.*, 2012, **14**, 2210–2213; (b) H. Wu, Y.-P. He, L. Xu, D.-Y. Zhang and L. Z. Gong, *Angew. Chem., Int. Ed.*, 2014, **53**, 3466–3469; (c) Y. Cao, X. Zhang, G. Lin, D. Zhang-Negrerie and Y. Du, *Org. Lett.*, 2016, **18**, 5580–5583.
- 11 (a) H. Yoon, A. Lossouarn, F. Landau and M. Lautens, *Org. Lett.*, 2016, **18**, 6324–6327; (b) J. Liu, H. Peng, L. Lu, X. Xu, H. Jiang and B. Yin, *Org. Lett.*, 2016, **18**, 6440–6443; (c) J. Liu, X. Xu, J. Li, B. Liu, H. Jiang and B. Yin, *Chem. Commun.*, 2016, **52**, 9550–9553; (d) J. Liu, H. Peng, Y. Yang, H. Jiang and B. Yin, *J. Org. Chem.*, 2016, **81**, 9695–9706.
- 12 (a) J.-R. Huang, M. Sohail, T. Taniguchi, K. Monde and F. Tanaka, *Angew. Chem., Int. Ed.*, 2017, **56**, 5853–5857; (b) B. M. Trost and M. K. Brennan, *Org. Lett.*, 2006, **8**, 2027–2030; (c) T. Arai, T. Miyazaki, H. Ogawa and H. Masu, *Org. Lett.*, 2016, **18**, 5824–5827.
- 13 (a) X. Fan, H. Yang and M. Shi, *Adv. Synth. Catal.*, 2017, **359**, 49–57; (b) S. Jia, Y. Lei, L. Song, A. Gopi Krishna Reddy, D. Xing and W. Hu, *Adv. Synth. Catal.*, 2017, **359**, 58–63; (c) L. Wang, S. Li, M. Blgmel, R. Puttreddy, A. Peuronen, K. Rissanen and D. Enders, *Angew. Chem., Int. Ed.*, 2017, **56**, 8516–8521.
- 14 Y. He, M. Lin, Z. Li, X. Liang, G. Li and J. C. Antilla, *Org. Lett.*, 2011, **13**, 4490–4493.
- 15 I. Čorić, S. Müller and B. List, *J. Am. Chem. Soc.*, 2010, **132**, 17370–17373.
- 16 (a) J.-H. Xie and Q.-L. Zhou, *Acc. Chem. Res.*, 2008, **41**, 581–593; (b) M. Jiang, S.-F. Zhu, Y. Yang, L.-Z. Gong, X.-G. Zhou and Q.-L. Zhou, *Tetrahedron: Asymmetry*, 2006, **17**, 384–387.

